Anti-LGI1 Encephalitis

Table of Contents

1. What LGI1 Is and Why Antibodies Attack It
2. Who Anti-LGI1 Encephalitis Affects
3. Faciobrachial Dystonic Seizures — The Warning Sign
4. Full Syndrome: Memory, Mood, and More
5. How It Is Diagnosed
6. Treatment and Why Timing Matters
7. Recovery and Long-Term Outlook
8. Key Research Papers
9. Connections
10. Featured Videos

What LGI1 Is and Why Antibodies Attack It

LGI1 stands for leucine-rich glioma inactivated 1. Despite the name (it was first found mutated in certain brain tumors), its main job in a healthy adult brain is to be a molecular bridge at synapses — the junctions where brain cells communicate with each other.

Picture a synapse as a handshake between two nerve endings. On the sending side, there are potassium channels (Kv1.1) that help control how electrically excitable the nerve is. On the receiving side, there are AMPA receptors that detect the chemical signal glutamate and generate the electrical response that encodes a memory or sensation. LGI1 connects these two sides via partner proteins called ADAM22 (on the receiving cell) and ADAM23 (on the sending cell). It acts like a scaffold that keeps the right number of AMPA receptors anchored in place and regulates how excitable the sending side is.

When anti-LGI1 antibodies bind to this protein, they disrupt the entire scaffold. AMPA receptors are pulled away from the synapse. The potassium channels on the sending side become dysregulated. The result is a limbic circuit — the loop of brain structures that forms memories, regulates emotion, and controls the body's autonomic functions — that can no longer function properly. Neurons fire when they should not (causing seizures) and fail to encode new information (causing amnesia).

This condition was formerly called anti-VGKC complex encephalitis (voltage-gated potassium channel complex encephalitis) because early tests measured antibodies to the entire complex of proteins. Later research showed that the actual pathogenic antibodies in most cases target either LGI1 or a related protein called CASPR2 — not the potassium channel itself. LGI1-antibody disease and CASPR2-antibody disease are now recognized as distinct conditions with different features and associations.

Back to Table of Contents

Who Anti-LGI1 Encephalitis Affects

Anti-LGI1 encephalitis affects middle-aged and older adults, with the average age at diagnosis in the 60s. It is distinctly different from the other major autoimmune encephalitis (anti-NMDA receptor encephalitis), which predominantly affects young women. Anti-LGI1 affects men roughly twice as often as women (2:1 male predominance).

One of the most striking discoveries in this disease is its powerful genetic link. Most people with the disease carry the immune gene variant HLA-DRB1*07:01. In a Korean study of 11 patients, 10 (91%) carried the DRB1*07:01-DQB1*02:02 combination, far more often than people in the control groups. In a 2025 European series of 238 patients, 89% carried DRB1*07:01 and 10% carried DRB1*04:02; people without DRB1*07:01 were younger, less often male, and more often had a poor outcome. This is one of the strongest human leukocyte antigen-disease associations in all of autoimmune neurology — stronger than most associations seen in rheumatoid arthritis or type 1 diabetes. It tells researchers that the immune system in these individuals is especially prone to misdirecting antibodies against LGI1, though the trigger that starts this process remains unknown.

Unlike some autoimmune encephalitides, anti-LGI1 encephalitis is usually not caused by cancer. The paraneoplastic rate (where the disease is driven by the body attacking a tumor that expresses LGI1) is low — roughly 5-10% of cases. Nevertheless, a computed tomography (CT) scan of the chest, abdomen, and pelvis is a standard part of the workup to look for thymoma or lung cancer, as these are the tumors occasionally associated with the condition.

Back to Table of Contents

Faciobrachial Dystonic Seizures — The Warning Sign

Before the full encephalitis syndrome develops, many patients experience a highly distinctive type of seizure that is essentially unique to anti-LGI1 encephalitis. These are called faciobrachial dystonic seizures (FBDS), and recognizing them early can prevent the development of permanent memory damage.

An FBDS episode looks like this: very suddenly, one arm shoots upward or twists into an unusual posture (like a dystonic jerk), while on the same side of the body, the face grimaces or twitches. The whole event lasts less than three seconds and the person is typically aware during it. Then it stops, just as abruptly as it started. This can happen dozens — sometimes more than 100 — times per day. Because they are so brief, patients and family members often wonder if they are "just a habit" or a tic.

These seizures have two peculiar features that confuse standard testing:

• Electroencephalogram (EEG) is often normal during the episode — because FBDS are too brief and arise from subcortical circuits, the brain-wave recording that doctors rely on to prove a seizure is occurring frequently shows nothing abnormal during the event itself.
• Anti-seizure medications alone do not control them well — standard drugs like carbamazepine reduce the frequency somewhat, but the seizures do not stop properly until the underlying autoimmune inflammation is treated. In a study of 103 patients, anti-seizure drugs alone stopped FBDS in only 9 of 89 (10%), while 51% stopped within 30 days of adding immunotherapy. In the first FBDS series (29 patients), anti-seizure drugs were generally ineffective and caused skin reactions, often severe, in 41%.

The critical finding from research is that starting immunotherapy during the FBDS phase — before the full limbic encephalitis develops — dramatically reduces the severity of memory loss and the risk of hippocampal damage. In patients treated at the FBDS stage, many avoid encephalopathy entirely. Waiting until memory fails means the brain has been under antibody attack for longer, and recovery is harder. This makes FBDS recognition one of the most important clinical tasks in neurology.

In the 103-patient study, 80 people whose illness began with FBDS were followed: 56% developed memory and thinking problems after 90 days of FBDS that kept going, while only one patient developed such problems after the FBDS had stopped. Faster immunotherapy and normal thinking at the start were both linked to less disability at 24 months.

Back to Table of Contents

Full Syndrome: Memory, Mood, and More

When the full limbic encephalitis syndrome develops — either because FBDS were not recognized or because some patients do not have FBDS at all — the presentation typically includes several overlapping problems that worsen over days to weeks:

Memory Loss

The most prominent feature is anterograde amnesia — the inability to form new memories. Patients can often recall their own name, their past life, and remote facts, but they cannot remember what they had for breakfast, whether they have already told you this story three times today, or where they are. This pattern can strongly resemble Alzheimer's disease, and many patients initially receive that diagnosis. The key difference is the speed of onset: Alzheimer's progresses over years; anti-LGI1 encephalitis can devastate short-term memory in days to weeks.

Psychiatric Symptoms

Personality changes, anxiety, paranoia, depression, and even frank psychosis frequently appear early and can dominate the picture. Many patients are admitted to psychiatric units first, where antipsychotic medications are used — they provide little benefit and can sometimes worsen the condition. This delay in reaching a neurologist is one of the most common and most damaging features of the diagnostic journey for this disease.

Seizures

Beyond FBDS, patients can develop temporal lobe seizures with auras of fear, déjà vu, rising abdominal sensations, or brief lapses in awareness. Status epilepticus (prolonged or back-to-back seizures) can also occur and is a medical emergency.

Hyponatremia (Low Sodium)

A striking and clinically important feature of anti-LGI1 encephalitis is profound hyponatremia (low blood sodium), typically caused by SIADH (syndrome of inappropriate antidiuretic hormone secretion). Sodium levels of 120–130 mmol/L (normal is ~135–145) are common. This degree of hyponatremia is dangerous on its own — it can cause brain swelling, additional confusion, and seizures. Sodium is corrected carefully: no faster than 10–12 mmol/L in any 24-hour period, because overcorrecting too quickly can cause osmotic demyelination syndrome (a serious, sometimes irreversible form of brain damage caused by the cells shrinking too fast). Treatment of hyponatremia in this condition typically involves fluid restriction and close electrolyte monitoring — and the hyponatremia itself often improves when the underlying encephalitis is treated with immunotherapy.

Sleep Disturbance and Autonomic Features

Many patients develop severe insomnia, vivid dreams, or REM sleep behavior disorder (acting out dreams, sometimes violently). Autonomic nervous system involvement can cause blood pressure instability, heart rate irregularities, and excessive sweating.

No fever is a useful distinguishing point: unlike viral or bacterial encephalitis, anti-LGI1 encephalitis typically does not cause fever, which can falsely reassure clinicians that infection has been excluded — and therefore no further workup is needed. Reviews stress that autoimmune encephalitis belongs in the differential even without fever.

Back to Table of Contents

How It Is Diagnosed

Diagnosis requires a combination of clinical recognition, blood and spinal fluid testing, brain imaging, and electrical brain monitoring. No single test is sufficient on its own.

Antibody Testing

The definitive test is anti-LGI1 immunoglobulin G (IgG) antibody detection using a cell-based assay (CBA) — a test where cells are engineered to express LGI1 on their surface and the patient's antibodies are applied. This is both sensitive and specific. Crucially, both serum (blood) and cerebrospinal fluid (CSF) are tested: CSF LGI1 antibodies are less sensitive than serum, so relying on cerebrospinal fluid alone will miss cases. Many patients are serum-positive but cerebrospinal fluid-negative.

Spinal Fluid (Cerebrospinal Fluid)

A lumbar puncture (spinal tap) is performed to exclude infection and look for inflammation. In anti-LGI1 encephalitis, the cerebrospinal fluid is usually normal or shows only mild abnormalities: a slight increase in white blood cells (mild pleocytosis, typically fewer than 20 cells) and mildly elevated protein. This normalcy can be deceptive — it is very different from the robust inflammation seen in viral encephalitis, and may lead clinicians to prematurely conclude "nothing is wrong."

Electroencephalogram (Brain Wave Recording)

Electroencephalogram typically shows temporal lobe slowing or epileptiform discharges (spike-wave activity) arising from one or both temporal lobes. As noted above, electroencephalogram is often uninformative during FBDS themselves, but abnormalities are usually present between episodes in patients with the full encephalitis syndrome.

Magnetic Resonance Imaging Brain

Magnetic resonance imaging (MRI) is essential and often shows characteristic abnormalities:

• Medial temporal lobe T2/FLAIR hyperintensity — bright signal in the hippocampus and amygdala on these magnetic resonance imaging sequences, indicating swelling and inflammation. This may be unilateral (one side) early on.
• Basal ganglia T2 hyperintensity — a specific clue to anti-LGI1 encephalitis; bright signal in structures deep in the brain (caudate, putamen) is seen in a subset of patients and is unusual in other autoimmune encephalitides.
• Follow-up magnetic resonance imaging: even patients who improve clinically with treatment often develop hippocampal atrophy (shrinkage) on later scans, reflecting permanent neuronal loss during the acute attack. This underlies the persistent memory difficulties some patients experience even after successful immunotherapy.

Tumor Workup

The standard workup includes a computed tomography of the chest, abdomen, and pelvis to screen for thymoma and lung cancer. If computed tomography is negative and clinical suspicion remains high, PET-CT may be considered. In most patients, no tumor is found.

Back to Table of Contents

Treatment and Why Timing Matters

Anti-LGI1 encephalitis is treatable, and earlier treatment means better outcomes. Treatment often starts before antibody results come back — if the clinical picture and initial tests (magnetic resonance imaging, electroencephalogram, cerebrospinal fluid) are consistent, most neurologists will begin immunotherapy immediately. In a 2026 international study of 181 patients (median age 63, 67% men), each month of delay before immunotherapy was linked to a 16% higher risk of lasting disability, and receiving no immunotherapy was linked to more disability at one year and to a relapsing course.

First-Line Immunotherapy

The standard urgent initial treatment uses two complementary approaches simultaneously or in rapid sequence:

• Intravenous (IV) methylprednisolone — a high-dose corticosteroid (typically 1 gram per day for 3–5 days intravenously), which broadly suppresses immune system activity and reduces brain inflammation rapidly.
• IVIG (intravenous immunoglobulin) — pooled human antibodies given intravenously at 2 g/kg total dose over 2–5 days. IVIG works by diluting and neutralizing the pathogenic LGI1 antibodies and modulating immune regulation.

Plasma exchange (plasmapheresis) — where the patient's blood plasma containing the antibodies is physically removed and replaced — is an effective alternative to IVIG and is sometimes used first in patients with more severe disease or when IVIG cannot be used (e.g., due to immunoglobulin A (IgA) deficiency). Typically 5–7 exchanges are performed.

What the studies show so far: the only placebo-controlled trial (IVIG versus saline, stopped early after 17 patients) found that seizures fell by half or more in 6 of 8 patients given IVIG versus 2 of 9 given placebo; among patients with LGI1 antibodies it was 6 of 8 versus 0 of 6. The authors note the trial did not reach its planned size. In the 2026 study of 181 patients, seizures stopping in the first weeks was linked to corticosteroids, plasma exchange and rituximab, but not to anti-seizure drugs, IVIG or steroid-sparing pills; seizures often came back after oral prednisolone was stopped. Rituximab was the only treatment linked to a lower risk of later relapse (93% lower). These are real-world findings, not randomized trial results.

Second-Line Immunotherapy

If the patient does not improve sufficiently within 2–4 weeks of first-line treatment, escalation to second-line agents is the usual next step:

• Rituximab — a monoclonal antibody that depletes B cells (the antibody-producing cells). Given as either four weekly infusions of 375 mg/m² or two doses of 1 gram two weeks apart. Rituximab has shown strong evidence of benefit in autoimmune encephalitis and is often preferred for patients who relapse or fail first-line treatment.
• Mycophenolate mofetil — an oral immunosuppressant (typically 1–1.5 g twice daily) that slows the production of new immune cells. Often used for long-term maintenance.
• Azathioprine — another oral maintenance immunosuppressant; used less frequently than mycophenolate but an option for patients who cannot tolerate it.

Duration of Treatment

Anti-LGI1 encephalitis tends to require sustained immunotherapy for two or more years. In a Dutch nationwide cohort of 38 patients, relapses occurred in 35% and appeared up to 8 years after the first illness; in the 2026 international study, 38% had a relapsing course. Relapses are more likely when treatment is stopped too early. Regular antibody titer monitoring and clinical follow-up guide decisions about tapering.

Managing Seizures

Anti-seizure medications are an important part of management but are chosen carefully:

• Levetiracetam is commonly chosen — it is effective, has no significant drug interactions with immunosuppressants, and does not worsen sodium disturbances.
• Enzyme-inducing anti-seizure drugs are generally not used — carbamazepine, oxcarbazepine, and phenytoin are relatively contraindicated. Carbamazepine and oxcarbazepine worsen hyponatremia (they cause SIADH themselves), compounding what is already a serious problem in anti-LGI1 encephalitis. All enzyme-inducing drugs also interact with steroids and other immunosuppressants, complicating dosing.
• FBDS are partially suppressed by levetiracetam and steroids, but the most important intervention for FBDS is immunotherapy — antiseizure drugs are an adjunct, not the solution.

Managing Hyponatremia

Sodium correction is kept gradual. The general rule is no more than 10–12 mmol/L in any 24-hour period. Most patients with anti-LGI1-associated hyponatremia are managed with fluid restriction (typically 1–1.5 liters per day). Hypertonic saline is reserved for severe or symptomatic cases. Electrolytes are typically checked every 4–6 hours during active correction. As the encephalitis responds to immunotherapy, the SIADH mechanism resolves and sodium levels normalize.

Back to Table of Contents

Recovery and Long-Term Outlook

The prognosis for anti-LGI1 encephalitis is better than many brain diseases, but it is important to have realistic expectations. This is not a condition that resolves in a few weeks and then disappears.

Approximately 80% of patients show meaningful clinical improvement with immunotherapy. In the Dutch nationwide cohort (38 patients), 80% had a substantial response to immunotherapy, with seizures improving early and thinking recovering slowly; 86% had lasting amnesia for the period of the illness. Swelling of the hippocampus on the first MRI (seen in 74%) often turned into scarring (mesial temporal sclerosis, 44%), and the two-year death rate was 19%. In those treated early — particularly in the FBDS phase before encephalopathy sets in — outcomes can be excellent, with near-complete recovery of memory and function. The brain has considerable plasticity, and removing the antibody attack allows damaged synapses to partially recover.

However, many patients are left with some degree of persistent memory difficulties, even after antibodies are cleared and seizures are controlled. This reflects structural damage: the hippocampi often shrink visibly on follow-up magnetic resonance imaging, indicating that some neurons did not survive the acute attack. Patients may have difficulty forming complex new memories or keeping track of appointments, even when they are able to live independently and have normal conversations.

Other realistic expectations:

• Relapses in 35% of patients in the Dutch nationwide cohort, appearing up to 8 years after the first illness. Symptoms on relapse may be milder or as severe as the initial episode. Relapses respond to re-treatment but highlight the need for long-term surveillance.
• Fatigue and cognitive fog are common in the months after the acute phase; many patients need cognitive rehabilitation and occupational therapy.
• Depression and anxiety can persist, both as direct effects of limbic system injury and as understandable psychological responses to the experience of losing memory and independence.
• Seizure freedom is achievable in most patients once immunotherapy is established; many patients are eventually able to taper anti-seizure medications.

The strongest predictor of good outcome is early diagnosis and early immunotherapy. In the 2026 study, each month of delay before immunotherapy was linked to a 16% higher risk of lasting disability, so the time it takes to reach autoimmune encephalitis antibody testing and a neurology assessment matters.

Back to Table of Contents

Key Research Papers

These are peer-reviewed studies published in leading neurology journals that established our current understanding of anti-LGI1 encephalitis. All citations link to PubMed, the U.S. National Library of Medicine's searchable database of medical research.

1. Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9(8):776–785. — PubMed PMID: 20580615
2. Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010;133(9):2734–2748. — PubMed PMID: 20663977
3. Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69(5):892–900. — PubMed PMID: 21416487
4. Thompson J, Bi M, Murchison AG, Makuch M, Bien CG, Chu K, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain. 2018;141(2):348–356. — PubMed PMID: 29272336
5. Kim TJ, Lee ST, Moon J, Sunwoo JS, Byun JI, Lim JA, et al. Anti-LGI1 encephalitis is associated with unique HLA subtypes. Ann Neurol. 2017;81(2):183–192. — PubMed PMID: 28026029
6. van Sonderen A, Schreurs MW, Wirtz PW, Sillevis Smitt PA, Titulaer MJ. From VGKC to LGI1 and Caspr2 encephalitis: the evolution of a disease entity over time. Autoimmun Rev. 2016;15(10):970–974. — PubMed PMID: 27485013
7. Finke C, Prüss H, Heine J, Reuter S, Kopp UA, Wegner F, et al. Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies. JAMA Neurol. 2017;74(1):50–59. — PubMed PMID: 27893017
8. Ariño H, Armangué T, Petit-Pedrol M, Sabater L, Martinez-Hernandez E, Hara M, et al. Anti-LGI1-associated cognitive impairment: presentation and long-term outcome. Neurology. 2016;87(8):759–765. — PubMed PMID: 27466467
9. van Sonderen A, Thijs RD, Coenders EC, Jiskoot LC, Sanchez E, de Bruijn MA, et al. Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology. 2016;87(14):1449–1456. — PubMed PMID: 27590293
10. Joubert B, Saint-Martin M, Noraz N, Picard G, Rogemond V, Ducray F, et al. Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures. JAMA Neurol. 2016;73(9):1115–1124. — PubMed PMID: 27428927
11. Gadoth A, Pittock SJ, Dubey D, McKeon A, Britton JW, Schmeling JE, et al. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. Ann Neurol. 2017;82(1):79–92. — PubMed PMID: 28628235
12. Navarro V, Kas A, Apartis E, Chami L, Rogemond V, Levy P, et al. Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. Brain. 2016;139(Pt 4):1079–1093. — PubMed PMID: 26945884
13. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404. — PubMed PMID: 26906964
14. Campetella L, Villagrán-García M, Farina A, Villard M, Benaiteau M, Vogrig A, et al. Clinical specificities and outcome of LGI1-antibody encephalitis according to age, sex and HLA. J Neurol Neurosurg Psychiatry. 2025;97(1):71–80. — PubMed PMID: 41093636
15. Dubey D, Britton J, McKeon A, Gadoth A, Zekeridou A, Lopez Chiriboga SA, et al. Randomized placebo-controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy. Ann Neurol. 2020;87(2):313–323. — PubMed PMID: 31782181
16. Ramanathan S, Soltys J, Michael S, Mackrill SV, Cleaver J, Williams R, et al. Short-term outcomes, longer-term disability and relapse risk in LGI1-antibody encephalitis. Brain. 2026. — PubMed PMID: 42934970

Search PubMed for more research:

1. PubMed: Anti-LGI1 encephalitis
2. PubMed: Faciobrachial dystonic seizures
3. PubMed: Autoimmune limbic encephalitis treatment
4. PubMed: LGI1 and CASPR2 antibody syndromes

Back to Table of Contents

Connections

• Neurology
• Anti-NMDA Receptor Encephalitis
• Epilepsy
• Stiff-Person Syndrome
• Lambert-Eaton Myasthenic Syndrome
• MOG Antibody Disease (MOGAD)
• Neuromyelitis Optica (NMOSD)
• Encephalitis — the broader condition, covering infectious and autoimmune causes.

Back to Table of Contents

Featured Videos

▶ Play All — Anti-LGI1 Encephalitis Videos

Back to Table of Contents